Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality

The use of senolytic agents to remove senescent cells from atherosclerotic lesions is controversial. A common limitation of previous studies is the failure to rigorously define the effects of senolytic agent ABT-263 (Navitoclax) on smooth muscle cells (SMC) despite studies claiming that they are the...

Descripción completa

Detalles Bibliográficos
Autores principales: Karnewar, Santosh, Karnewar, Vaishnavi, Shankman, Laura S., Owens, Gary K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369968/
https://www.ncbi.nlm.nih.gov/pubmed/37502944
http://dx.doi.org/10.1101/2023.07.12.548696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369968/
https://www.ncbi.nlm.nih.gov/pubmed/37502944
http://dx.doi.org/10.1101/2023.07.12.548696

Ejemplares similares